Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: The French TMA Reference Center experience

Haematologica

Volumn 97, Issue 8, 2012, Pages 1181-1186

  Benhamou, Ygal ^a   Assié, Cyrielle ^a   Boelle, Pierre Yves ^b,c   Buffet, Marc ^d   Grillberger, Rana ^e   Malot, Sandrine ^d   Wynckel, Alain ^f   Presne, Claire ^g   Choukroun, Gabriel ^g   Poullin, Pascale ^h   Provôt, François ⁱ   Gruson, Didier ^j   Hamidou, Mohamed ^k   Bordessoule, Dominique ^l   Pourrat, Jacques ^m   Mira, Jean Paul ⁿ   Le Guern, Véronique ^o   Pouteil Noble, Claire ^p   Daubin, Cédric ^q   Vanhille, Philippe ^r   Rondeau, Eric ^s   Palcoux, Jean Bernard ^t   Mousson, Christiane ^u   Vigneau, Cécile ^v   Bonmarchand, Guy ^a   Guidet, Bertrand ^c,d   Galicier, Lionel ^w   Azoulay, Elie ^x   Rottensteiner, Hanspeter ^e   Veyradier, Agnès ^y   Coppo, Paul ^d   more..

^a HÔPITAL CHARLES NICOLLE   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e BAXTER INNOVATIONS GMBH   (Austria)

^f HÔPITAL MAISON BLANCHE   (France)

^g AMIENS UNIVERSITY HOSPITAL   (France)

^h HÔPITAL DE LA CONCEPTION   (France)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j HÔPITAL PELLEGRIN   (France)

^k HÔTEL DIEU   (France)

^l DUPUYTREN UNIVERSITY HOSPITAL   (France)

^m CHU RANGUEIL   (France)

ⁿ Service de Réanimation Polyvalente CH Victor Dupouy   (France)

^o Hôpital Cochin ^*  (France)

^p UNIVERSITÉ LYON 1   (France)

^q CAEN UNIVERSITY HOSPITAL   (France)

^r CENTRE HOSPITALIER DE VALENCIENNES   (France)

^s HÔPITAL TENON   (France)

^t Service de Néphrologie Pédiatrique   (France)

^u Service De Néphrologie   (France)

^v PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^w Service d'Immunopathologie   (France)

^x SAINT LOUIS HOSPITAL   (France)

^y HÔPITAL ANTOINE BÉCLÈRE   (France)

more..

Author keywords

ADAMTS13; Plasma exchange; Prognostic factor; Rituximab; Thrombotic thrombocytopenic purpura

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; LACTATE DEHYDROGENASE; RITUXIMAB; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACCURACY; ADULT; AGE; AGED; ARTICLE; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; DEATH; FEMALE; HEMODIALYSIS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MODEL; MORTALITY; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN DEFICIENCY; RISK; SENSITIVITY AND SPECIFICITY; SPLENECTOMY; THROMBOCYTE TRANSFUSION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VALIDATION PROCESS;

ADAM PROTEINS; ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROGNOSIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; REGISTRIES; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 84864764918     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.049676     Document Type: Article

References (34)

1. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008;112(1):11-8.
2. Klaus C, Plaimauer B, Studt JD, Dorner F, Lammle B, Mannucci PM, et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood. 2004;103(12):4514-9.
3. Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, et al. A phase II study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118(7):1746-53.
4. Froissart A, Buffet M, Veyradier A, Poullin P, Provot F, Malot S, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012;40(1):104-11.
5. Franchini M, Mannucci PM. Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura. Blood Transfus. 2008;6(3):127-35.
6. Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500-11;quiz 662.
7. Pereira A, Mazzara R, Monteagudo J, Sanz C, Puig L, Martinez A, et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol. 1995;70(6):319-23.
8. Rose M, Eldor A. High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical study of 38 patients. Am J Med. 1987;83(3):437-44.
9. Rock G, Kelton JG, Shumak KH, Buskard NA, Sutton DM, Benny WB. Laboratory abnormalities in thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Br J Haematol. 1998;103(4):1031-6.
10. Patton JF, Manning KR, Case D, Owen J. Serum lactate dehydrogenase and platelet count predict survival in thrombotic thrombocytopenic purpura. Am J Hematol. 1994;47(2):94-9.
11. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325(6):393-7.
12. Bobbio-Pallavicini E, Gugliotta L, Centurioni R, Porta C, Vianelli N, Billio A, et al. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica. 1997;82(4):429-35.
13. Wyllie BF, Garg AX, Macnab J, Rock GA, Clark WF. Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange. Br J Haematol. 2006;132(2):204-9.
14. Lotta LA, Mariani M, Consonni D, Mancini I, Palla R, Maino A, et al. Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. Br J Haematol. 2010;151(5):488-94.
15. Zheng XL, Wu HM, Shang D, Falls E, Skipwith CG, Cataland SR, et al. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica. 2010;95(9):1555-62.
16. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103(11):4043-9.
17. Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol. 2006;132 (1):66-74.
18. Tsai HM. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura. Am J Hematol. 2000;65(3):251-5.
19. Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One.2010;5(4):e10208.
20. Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P, et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood. 2007;109(7):2815-22.
21. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837-45.
22. Dervenoulas J, Tsirigotis P, Bollas G, Pappa V, Xiros N, Economopoulos T, et al. Thrombotic thrombocytopenic purpura/ hemolytic uremic syndrome (TTP/HUS): treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases. Ann Hematol. 2000;79(2):66-72.
23. Scheiflinger F, Knobl P, Trattner B, Plaimauer B, Mohr G, Dockal M, et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood. 2003; 102(9):3241-3.
24. Eymin G, Andrade M, Andresen M, Pereira J. [Thrombotic thrombocytopenic purpura: experience in 18 cases and literature review]. Rev Med Chil. 2008;136(12):1518-27.
25. Lara PN Jr, Coe TL, Zhou H, Fernando L, Holland PV, Wun T. Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Am J Med. 1999; 107(6):573-9.
26. Thorin E, Thorin-Trescases N. Vascular endothelial ageing, heartbeat after heartbeat. Cardiovasc Res. 2009;84(1):24-32.
27. O'Rourke MF. Arterial aging: pathophysiological principles. Vasc Med. 2007;12(4): 329-41.
28. Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher. 1998;13(1):16-9.
29. Berkowitz LR, Dalldorf FG, Blatt PM. Thrombotic thrombocytopenic purpura: a pathology review. JAMA. 1979;241(16): 1709-10.
30. Patschan D, Witzke O, Duhrsen U, Erbel R, Philipp T, Herget-Rosenthal S. Acute myocardial infarction in thrombotic microangiopathies--clinical characteristics, risk factors and outcome. Nephrol Dial Transplant. 2006;21(6):1549-54.
31. Hawkins BM, Abu-Fadel M, Vesely SK, George JN. Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion. 2008; 48(2):382-92.
32. Hughes C, McEwan JR, Longair I, Hughes S, Cohen H, Machin S, et al. Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13. J Thromb Haemost. 2009;7(4):529-36.
33. Clark WF, Forzley BR, Sontrop JM, Kadri A, Moist LM, Suri RS, et al. TTP/HUS: observational studies generate hypotheses that lead to randomized controlled trials. Kidney Int Suppl. 2009;112:S50-1.
34. Noris P, Balduini CL. Investigational drugs in thrombotic thrombocytopenic purpura. Expert Opin Investig Drugs. 2011;20(8): 1087-98